SeQuent Eyes Ebitda Growth Of 200 Basis Points Or More In Fourth Quarter
The animal healthcare company also looks to tap into multibillion dollar foreign markets to expand its growth potential.
Animal healthcare company SeQuent Scientific Ltd. said it expects its fourth quarter Ebitda margin to see a growth of at least 200 basis points, with a run rate edging over Rs 300 crore.
“We should be at least Rs 2,000 crore company in three years time, with an Ebitda of anything between 18 to 20 percent,” SeQuent’s Chief Executive Officer Manish Gupta told BloombergQuint in an interview.
Gupta said the company is looking to tap into key foreign markets, including the U.S., to buoy its growth strategies. The U.S. accounts for almost 35 percent of global animal healthcare industry and thus, cannot be ignored, Gupta said, adding that the company has already registered 14 of its active pharmaceutical ingredients in the country and aims to initiate the first filing of its formulation in the next one year.
The company, according to Gupta, might look for a small acquisition or set up its own sales and marketing business in the U.S. to strengthen its growth trajectory in about 12 months.